Publications by authors named "Susan Thackwray"
Article Synopsis
- The study focuses on ARO-APOC3, an RNA interference therapy aimed at lowering triglyceride levels by inhibiting the APOC3 protein that hinders triglyceride clearance.
- The trial assessed safety, pharmacodynamics, and pharmacokinetics in healthy participants and those with hypertriglyceridemia, with doses administered via subcutaneous injections.
- Results showed that while there were some mild liver enzyme changes in a few participants receiving ARO-APOC3, these were asymptomatic and resolved, and the treatment significantly reduced APOC3 levels compared to the placebo group.
Interleukin (IL)-17A underlies the pathogenesis of chronic plaque psoriasis (CPP). Well-tolerated, effective IL-17A inhibitors for mild-to-moderate CPP are needed. ZL-1102 is a novel antibody fragment targeting IL-17A.
View Article and Find Full Text PDFBackground: In animal, epidemiological, and human challenge studies, a pre-existing T-cell response to internal proteins of influenza A has been associated with improved virological and disease outcomes. The aim of this study was to assess whether inducing additional responses to conserved CD4 and CD8 T-cell antigens provides added benefit to standard influenza vaccination.
Methods: We designed a phase 2b, randomised, placebo-controlled, double-blind trial of a recombinant viral-vectored vaccine (modified vaccinia Ankara expressing virus nucleoprotein and matrix protein 1; MVA-NP+M1), which has been shown to induce both CD4 and CD8 T cells, at eight outpatient clinical trial sites in Australia over two consecutive influenza seasons.